Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-01-06FDA Approved: SOLIFENACIN SUCCINATE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for solifenacin succinate from Actavis Pharma, Inc., authorizing a change related to this generic fo…
-
CLINICAL_TRIALS trial_result · 2021-01-05Clinical Trial Update: Mirabegron For Erectile Dysfunction [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating mirabegron for erectile dysfunction has completed, with results posted in 2021.
-
FDA approval · 2020-12-23FDA Approved: GEMTESA — Original Application (Sumitomo Pharma America, Inc.)
FDA approved GEMTESA (vibegron) as an original application for the treatment of overactive bladder.
-
FDA approval · 2020-12-17FDA Approved: OXYBUTYNIN CHLORIDE — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved the original application for a generic oxybutynin chloride product from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceutical…
-
FDA approval · 2020-11-24FDA Approved: SOLIFENACIN SUCCINATE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for solifenacin succinate from Glenmark Pharmaceuticals Inc., USA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-11-13Clinical Trial Update: Mirabegron and Urinary Urgency Incontinence [Phase 4]
Phase 4 trial update on mirabegron for urinary urgency incontinence due to overactive bladder; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-11-12Clinical Trial Update: NOGO for an Overactive Bladder [Phase 2]
Phase 2 clinical trial update for NOGO targeting overactive bladder and nocturia; status is currently unknown.
-
FDA approval · 2020-11-05FDA Approved: SOLIFENACIN SUCCINATE — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s supplemental application for solifenacin succinate (ANDA205483), confirming continued approval of the …
-
CLINICAL_TRIALS trial_result · 2020-11-05Clinical Trial Update: Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A [Phase 4]
Phase 4 clinical trial evaluating post-procedural pain associated with 5 versus 20 intravesical injections of onabotulinumtoxin A for overac…
-
FDA approval · 2020-10-30FDA Approved: SOLIFENACIN SUCCINATE — Supplemental Application (Alembic Pharmaceuticals Limited)
The FDA approved a supplemental application for Alembic Pharmaceuticals Limited to market a generic solifenacin succinate product.
-
FDA approval · 2020-10-27FDA Approved: OXYBUTYNIN CHLORIDE — Original Application (Advagen Pharma Limited)
FDA approved the generic oxybutynin chloride tablet from Advagen Pharma Limited under an Original Application.
-
CLINICAL_TRIALS trial_result · 2020-10-20Clinical Trial Update: Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream. [Phase 3]
Phase 3 study evaluating real-world use of an adhesive skin patch (Oxytrol) delivering oxybutynin for overactive bladder; status completed w…
-
FDA approval · 2020-08-05FDA Approved: TOLTERODINE TARTRATE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved tolterodine tartrate under an Original Application (ANDA) from Unichem Pharmaceuticals (USA), Inc., making a generic version of…
-
CLINICAL_TRIALS trial_result · 2020-07-28Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of MEDITOXIN® in individuals with idiopathic overactive bladder.
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: Percutaneous Nerve Evaluation With Fluoroscopy Versus Without [NA]
A completed clinical trial comparing percutaneous nerve evaluation with fluoroscopy versus without; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-05-29Clinical Trial Update: Oral vs Intravesical Analgesia for Office Bladder Botox Injections [Phase 4]
A Phase 4 trial comparing oral versus intravesical analgesia for office-based bladder Botox injections in overactive bladder conditions is u…
-
FDA approval · 2020-05-26FDA Approved: VESICARE LS — Original Application (Astellas Pharma US, Inc.)
FDA approved Vesicare LS (solifenacin succinate) under an original NDA from Astellas Pharma US, Inc. for the treatment of overactive bladder…
-
FDA approval · 2020-05-26FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for Vesicare (solifenacin succinate) submitted by Astellas Pharma US, Inc. The approval results in c…
-
FDA approval · 2020-05-19FDA Approved: TOLTERODINE TARTRATE — Original Application (Ajanta Pharma USA Inc.)
FDA approves Ajanta Pharma USA Inc.'s original application for tolterodine tartrate (generic tolterodine tartrate), a treatment for overacti…
-
CLINICAL_TRIALS trial_result · 2020-04-28Clinical Trial Update: Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder [Phase 4]
A Phase 4 trial comparing standard injections to reduced injections of intravesical onabotulinumtoxinA for overactive bladder is currently r…
-
FDA approval · 2020-04-23FDA Approved: TROSPIUM CHLORIDE — Original Application (Granules Pharmaceuticals Inc.)
FDA approved an original ANDA for Trospium chloride (Granules Pharmaceuticals Inc.), a generic formulation for overactive bladder. The appro…
-
FDA approval · 2020-04-06FDA Approved: OXYBUTYNIN CHLORIDE — Original Application (Leading Pharma, LLC)
FDA approved Leading Pharma, LLC's original Abbreviated New Drug Application for oxybutynin chloride, enabling a generic version of this ant…
-
FDA approval · 2020-03-13FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for oxybutynin chloride from Amneal Pharmaceuticals LLC, updating the approval of the existing gener…
-
FDA approval · 2020-03-09FDA Approved: TOLTERODINE TARTRATE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Tolterodine tartrate (Tolterodine) by Torrent Pharmaceuticals Limited.
-
FDA approval · 2020-03-09FDA Approved: TOLTERODINE TARTRATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for tolterodine tartrate submitted by Teva Pharmaceuticals USA, Inc. This action confirms the contin…